Clinical trial NCT04097379: Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA
Official title: A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Osteoarthritis (OA)
Keywords: Knee osteoarthritis
Chondroanabolic drug
Magnetic resonance imaging
Patient Reported Outcomes
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2019-09-20
Enrollment: 45
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will explore the preliminary efficacy of multiple intra-articular injections of LRX712 by evaluating the ability of the drug to restore structural integrity of articular cartilage. Efficacy will be evaluated in the context of the systemic safety and local tolerability of the investigational drug.

Detailed description: The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of multiple intra-articular injections of LRX712 in the knee when treating patients with knee osteoarthritis of mild/moderate severity, in order to support the further clinical development. This study will also allow refinement of the systemic and local pharmacokinetics of LRX712 and the exploration of drug effects on biomarkers of cartilage breakdown and regeneration in OA patients.

Eligibility criteria: Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed.

To be eligible for inclusion in this study patients must meet all of the following criteria:

* Patient must have a BMI between 18 -35 kg/m2
* Patient must have symptomatic knee osteoarthritis predominantly in one knee (index knee)
* Patient must have knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) in the index knee, as confirmed by radiography
* Patient must have radiographic confirmation of a medial joint space width of 1.5 to 3.5 mm for females, or 2 to 4 mm for males within the medial tibio-femoral compartment of the index knee

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for inclusion in this study:

* Patient has a known autoimmune disease, inflammatory or chronic arthropathy
* Patient had partial or complete joint replacement in one or both knees
* Patient has symptomatic, isolated patello-femoral pain in the index knee as per the Investigator's examination
* Pregnant or nursing (lactating) women
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
* Previous use of LRX712 or use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
* Patient has malalignment (valgus- or varus-deformity) ≥ 7.5° in the index knee as per anatomic PA axis measured by weight-bearing short knee radiography
* History of significant cardiac conduction/electrophysiological disorder, e.g. familial long QT syndrome or known family history of Torsades de Pointes or prolonged QT syndrome or QTcF ≥ 450 msec (Fridericia Correction) for males and ≥ 460 msec for females at screening or baseline (by local 12-lead digitized ECG reading)
* Signs or symptoms, in the judgment of the investigator, of a clinically significant systemic viral, bacterial or fungal infection within 30 days prior to screening.

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Changes from baseline in cartilage volume in the medial femoral condyle at Week 28
timeFrame: Baseline and Week 28
Secondary outcomes:
measure: Changes in articular cartilage [23Na] content from baseline compared to placebo at Week 16, 28 and 52
timeFrame: Baseline, Week 16, 28 and 52
measure: Changes from baseline in cartilage volume in the medial femoral condyle at Week 16 and 52
timeFrame: Baseline, Week 16 and 52
measure: Time to Reach the Maximum Plasma Concentration (Tmax)
timeFrame: Pre-dose to 28 weeks
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: Pre-dose to 28 weeks
measure: Minimum Observed Plasma Concentration (Cmin)
timeFrame: Pre-dose to 28 weeks
measure: Concentration in synovial fluid
timeFrame: Day 1; week 4; week 8
measure: Local and systemic adverse events
timeFrame: Day 1 to 52 weeks
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: